Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-05-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2019.1578597 |
| _version_ | 1797677409301954560 |
|---|---|
| author | Ilaria Loperto Andrea Simonetti Antonio Nardone Maria Triassi |
| author_facet | Ilaria Loperto Andrea Simonetti Antonio Nardone Maria Triassi |
| author_sort | Ilaria Loperto |
| collection | DOAJ |
| description | Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) and quadrivalent (QIV) inactivated vaccines, adjuvanted TIV (aTIV). Because of immunosenescence, aTIV has been specifically developed for elderly. The present study aimed at assessing the available evidence of aTIV use in elderly from the economic perspective. A systematic literature review targeting aTIV economic evaluations in adults aged ≥65 years was performed using Medline via Ovid, Embase, DARE and NHS/EED. Of a total of 3,654 papers screened, 18 studies (13 full papers, 5 conference abstracts) were included. It emerged that compared with both non-vaccination or non-adjuvanted vaccines, aTIV was cost-effective or cost-saving. The vaccinations strategies incorporating aTIV based on age and/or risk profile are associated with the most favorable economic outcomes. |
| first_indexed | 2024-03-11T22:44:49Z |
| format | Article |
| id | doaj.art-676decc85f1f400387d6806587bf87f2 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:44:49Z |
| publishDate | 2019-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-676decc85f1f400387d6806587bf87f22023-09-22T08:38:26ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-05-011551035104710.1080/21645515.2019.15785971578597Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidenceIlaria Loperto0Andrea Simonetti1Antonio Nardone2Maria Triassi3University of Naples “Federico II”University of Naples “Federico II”University of Naples “Federico II”University of Naples “Federico II”Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) and quadrivalent (QIV) inactivated vaccines, adjuvanted TIV (aTIV). Because of immunosenescence, aTIV has been specifically developed for elderly. The present study aimed at assessing the available evidence of aTIV use in elderly from the economic perspective. A systematic literature review targeting aTIV economic evaluations in adults aged ≥65 years was performed using Medline via Ovid, Embase, DARE and NHS/EED. Of a total of 3,654 papers screened, 18 studies (13 full papers, 5 conference abstracts) were included. It emerged that compared with both non-vaccination or non-adjuvanted vaccines, aTIV was cost-effective or cost-saving. The vaccinations strategies incorporating aTIV based on age and/or risk profile are associated with the most favorable economic outcomes.http://dx.doi.org/10.1080/21645515.2019.1578597influenzavaccinetrivalentadjuvatedmf59older agesystematic revieweconomic evidence |
| spellingShingle | Ilaria Loperto Andrea Simonetti Antonio Nardone Maria Triassi Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence Human Vaccines & Immunotherapeutics influenza vaccine trivalent adjuvated mf59 older age systematic review economic evidence |
| title | Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence |
| title_full | Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence |
| title_fullStr | Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence |
| title_full_unstemmed | Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence |
| title_short | Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence |
| title_sort | use of adjuvanted trivalent influenza vaccine in older age adults a systematic review of economic evidence |
| topic | influenza vaccine trivalent adjuvated mf59 older age systematic review economic evidence |
| url | http://dx.doi.org/10.1080/21645515.2019.1578597 |
| work_keys_str_mv | AT ilarialoperto useofadjuvantedtrivalentinfluenzavaccineinolderageadultsasystematicreviewofeconomicevidence AT andreasimonetti useofadjuvantedtrivalentinfluenzavaccineinolderageadultsasystematicreviewofeconomicevidence AT antonionardone useofadjuvantedtrivalentinfluenzavaccineinolderageadultsasystematicreviewofeconomicevidence AT mariatriassi useofadjuvantedtrivalentinfluenzavaccineinolderageadultsasystematicreviewofeconomicevidence |